+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma



Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma



Oncology 80(3-4): 188-194



The purpose of this retrospective study was to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) with miriplatin in patients with unresectable hepatocellular carcinoma (HCC). From 2007 to 2010, 122 consecutive patients with unresectable HCC were treated by TACE with miriplatin-lipiodol suspension in our institute. Twenty-two patients (18%) had a solitary nodule and 100 patients (82%) had multiple nodules. Ninety-eight patients (80%) had a history of TACE. Thirty-five of the 122 treated patients (29%) showed complete response (CR). And no serious complications were observed. Patients who had shown CR after previous TACE (pre-CR) were significantly more likely to show CR in the current study compared with patients who had shown less successful responses after previous TACE (56 vs. 20%, p = 0.003). Multivariate analysis revealed that response after previous TACE (pre-CR, risk ratio: 4.76; p = 0.035), tumor multiplicity (solitary, risk ratio: 9.69; p = 0.003), and injection artery (peripheral to segmental hepatic artery, risk ratio: 5.28;p = 0.040) were significant independent predictors associated with CR after TACE using miriplatin. In repetition of TACE treatment, switching the TACE agent from epirubicin or cisplatin to miriplatin offered a favorable treatment effect, especially in patients who had shown a CR after previous TACE.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 055172124

Download citation: RISBibTeXText

PMID: 21709428

DOI: 10.1159/000328749


Related references

Mo2028 Comparison Between Transcatheter Arterial Chemoembolization (Tace) and Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) for Treatment of Intermediate Hepatocellular Carcinoma. Gastroenterology 144(5): S-722, 2013

P.13.7 Comparison Between Transcatheter Arterial Chemoembolization (Tace) And Transcatheter Arterial Chemoembolization Combined With Percutaneous Radiofrequency Ablation (Tace-Rfa) For Treatment Of Intermediate Hepatocellular Carcinoma (Hcc). Digestive and Liver Disease 45: S183-S184, 2013

Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. Radiology 280(2): 630-639, 2016

The Clinical Impact of Transcatheter Arterial Chemoembolization (TACE)-Induced c-Met Upregulation on TACE Refractoriness in Hepatocellular Carcinoma. Digestive Diseases and Sciences 61(6): 1572-1581, 2016

Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE. Journal of BUON 21(4): 909-916, 2017

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma. Journal of Evidence-Based Complementary & Alternative Medicine 22(4): 883-891, 2017

Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovascular and Interventional Radiology 31(4): 756-761, 2008

Systematic Review and Meta-analysis of Endostar Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone for Hepatocellular Carcinoma. Journal of Evidence-Based Complementary and Alternative Medicine 22(4): 883-891, 2017

Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovascular and Interventional Radiology 35(6): 1363-1371, 2012

Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching. Hepatology Research 49(8): 919-928, 2019

Is drug-eluting bead transcatheter arterial chemoembolization (TACE) associated with better tumor response than conventional TACE in meta-analysis?. Hepatology Research 45(12): 1258-1259, 2015

Analysis of tumor recurrence factors in patients of primary hepatocellular carcinoma with postoperative transcatheter arterial chemoembolization TACE. The Chinese-German Journal of Clinical Oncology 11(4): 206-209, 2012

Tu1486 - Development of a Hepatocellular Carcinoma Tumor Regression Grading System to Assess Treatment Response to Transcatheter Arterial Chemoembolization (Tace). Gastroenterology 154(6): S-1234-S-1235, 2018

Transcatheter arterial chemoembolization (TACE) combined with γ-knife compared to TACE or γ-knife alone for hepatocellular carcinoma. Medicine 97(22): E10890, 2018

Transcatheter arterial chemoembolization tace in patients affected by hepatocellular carcinoma hcc. Gastroenterology 100(5 Part 2): A403, 1991